함께 비교하는 진짜 ADC · Antibody · CGT 데이터

AntibodyInstitut BergoniéPhase 2

atezolizumab (Tecentriq, Association atezolizumab + BDB001 + RT)

Solid Tumor, Adult; Pancreatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#항체#면역항체+5

AntibodystaleMedical College of WisconsinPhase 1

atezolizumab (Tecentriq, Concurrent Atezolizumab)

Head and Neck Neoplasm · Head and Neck Neoplasm

#HeadandNeckNeoplasm#Antibody#Phase1#항체#면역항체+2

AntibodystaleMedical College of WisconsinPhase 1

atezolizumab (Tecentriq, Adjuvant Atezolizumab)

Head and Neck Neoplasm · Head and Neck Neoplasm

#HeadandNeckNeoplasm#Antibody#Phase1#항체#면역항체+2

AntibodystaleShanghai Henlius BiotechPhase 3

carboplatin-etoposide (Serplulimab + chemotherapy, Serplulimab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#항체#면역항체+2

AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4

ADCBiologicstaleTORL Biotherapeutics, LLCPhase 1

TORL-3-600 (TORL-3-600)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Fexagratinib (Fexagratinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

POLA-R-CHP+orelabrutinib (POLA-R-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3

AntibodystaleKymab LimitedPhase 2

Alomfilimab (Alomfilimab)

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#항체#면역항체+3

효능 ORR 0%임상시험 1상태 DISCONTINUED

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

R-miniCHOP +orelabrutinib (R-miniCHOP +orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

AntibodystaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#항체#면역항체+2

AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3

AntibodystaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#항체#면역항체+3

효능 ORR 7%임상시험 1상태 RECRUITING

AntibodystaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+2

AntibodystaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+2

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

POLA-Hi-CHP+orelabrutinib (POLA-Hi-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

AntibodystaleShuhong YiPhase 2

atezolizumab (Tecentriq, Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab)

Recurrent Liver Cancer After Liver Transplantation · Recurrent Liver Cancer After Liver Trans

#RecurrentLiverCancerAfterLiverTr#Antibody#Phase2#항체#면역항체+2

AntibodystaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#항체#면역항체+2

AntibodystaleCorvus Pharmaceuticals, Inc.Phase 1

atezolizumab (Tecentriq, Ciforadenant + atezolizumab)

Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase1#항체#면역항체+3

AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4

효능 ORR 64.6%임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#항체#면역항체+4

효능 ORR 87.5%임상시험 1상태 ACTIVE

AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4

효능 ORR 42.9%임상시험 1상태 ACTIVE

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

Hi-miniCHOP +orelabrutinib (Hi-miniCHOP +orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma